Aptevo Therapeutics Finalizes Terms for Highly Dilutive $60M Equity Line of Credit

summarizeSummary

This 424B4 filing finalizes the terms and enables the resale of shares under the $60 million Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., which was previously announced on January 9, 2026. The potential issuance of 7,075,471 shares represents an extraordinary dilution of over 900% of the company's currently outstanding common stock. While the capital infusion is critical for funding pipeline development and general corporate purposes, especially given the company's history of multiple reverse stock splits and ongoing Nasdaq listing compliance challenges, the deep discount pricing (96% of VWAP) and massive dilution signal significant financial distress and will likely exert substantial downward pressure on the stock price. Investors should be aware of the severe dilutive impact and the company's precarious financial position.

check_boxKey Events

• Finalizes Equity Line Terms

  This prospectus enables the resale of shares under the $60 million Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., operationalizing the capital raise initiated on January 9, 2026.

• Extreme Share Dilution

  The offering involves up to 7,075,471 shares, representing over 900% of the 767,164 shares outstanding as of September 30, 2025, indicating a highly dilutive event for existing shareholders.

• Discounted Share Sales

  Shares will be sold to YA at a discount, specifically 96% of the lowest of three daily Volume Weighted Average Prices (VWAPs) during a pricing period, reflecting unfavorable terms for the company.

• Capital for Operations

  Proceeds from sales to YA will fund research and development, new programs, business development, and general corporate purposes, providing crucial liquidity for the cash-strapped biotech.

auto_awesomeAnalysis

This 424B4 filing finalizes the terms and enables the resale of shares under the $60 million Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., which was previously announced on January 9, 2026. The potential issuance of 7,075,471 shares represents an extraordinary dilution of over 900% of the company's currently outstanding common stock. While the capital infusion is critical for funding pipeline development and general corporate purposes, especially given the company's history of multiple reverse stock splits and ongoing Nasdaq listing compliance challenges, the deep discount pricing (96% of VWAP) and massive dilution signal significant financial distress and will likely exert substantial downward pressure on the stock price. Investors should be aware of the severe dilutive impact and the company's precarious financial position.